| Entry |
|
|---|
| Name |
Hydroxyurea (USP);
Hydroxycarbamide (JAN/INN);
Droxia (TN);
Hydrea (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
CH4N2O2
|
|---|
| Exact mass |
76.0273
|
|---|
| Mol weight |
76.0547
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Remark |
| Therapeutic category: | 4229 |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
Chronic myeloid leukemia [DS: H00004] Squamous cell carcinomas of the head and neck [DS: H02420] Sickle cell anemia [DS: H00229] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX05 Hydroxycarbamide
D00341 Hydroxyurea (USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Hydroxyurea
D00341 Hydroxyurea (USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4229 Others
D00341 Hydroxyurea (USP); Hydroxycarbamide (JAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Ribonucleoside-diphosphate reductase
RRM2
D00341 Hydroxyurea (USP) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00341
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 5
1 C5a C 25.2773 -18.3400
2 N1b N 26.4812 -19.0436
3 N1a N 24.0675 -19.0436
4 O5a O 25.2773 -16.9385
5 O1b O 27.6967 -18.3400
BOND 4
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
|
|---|
